Elvina Almuradova: Promising First-Line Treatment for BRAF V600E-Mutant mCRC
Elvina Almuradova, Oncology Unit Lead at Can Hospitals Turkey, shared a post on LinkedIn:
“BREAKWATER Trial:
Promising First-Line Treatment for BRAF V600E-Mutant mCRC
The phase 3 BREAKWATER trial (Abstract 16, GI25) evaluated encorafenib + cetuximab (EC) with mFOLFOX6 in first-line treatment for BRAF V600E-mutant metastatic colorectal cancer (mCRC).
– Overall Response Rate (ORR): 60.9% with EC + mFOLFOX6 vs. 40.0% with standard chemotherapy (SOC).
– Durability: 68.7% of patients on EC + mFOLFOX6 had responses lasting ≥6 months vs. 34.1% on SOC.
– Interim Overall Survival (OS): Median OS not yet reached (EC + mFOLFOX6), with a hazard ratio of 0.47 (P=0.0000454).
EC + mFOLFOX6 demonstrates improved efficacy, higher response rates, and durability compared to SOC, with a positive trend in OS. These findings highlight a promising step forward for patients with this challenging mCRC subtype.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023